What is TERN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.12B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TERN?

P/E (TTM) is n/a and 52-week range is $6.99 to $53.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TERN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TERN?

The company profile lists net income (TTM) near -$119M, EPS (TTM) near -$1.03 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Terns Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Foster City, California, US, 115.5M shares outstanding, ISIN US8808811074 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Terns Pharmaceuticals Inc

$TERN

Health Care · Pharmaceuticals

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 59 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). The company is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Employees

Website

ternspharma.com/

IPO

2021-02-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)